Healthcare & Pharmaceutical Market Research in South Korea

BioNixus is a leading healthcare market research company in South Korea, delivering Korean-language HCP surveys, KOL mapping, and payer landscape research aligned with MFDS (Ministry of Food and Drug Safety), HIRA (Health Insurance Review and Assessment Service), and NHIS (National Health Insurance Service) requirements. BioNixus combines primary research depth with physician access across Korea's Big 5 hospitals and specialist community networks.

A healthcare market research company in South Korea designs and executes studies covering physician prescribing behaviour, HIRA/NHIS payer and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the South Korean market.

South Korea operates a positive list reimbursement system combining MFDS regulatory approval, HIRA pharmacoeconomic evaluation, NHIS positive list coverage decisions, and NECA independent HTA assessment — creating a multi-stage access journey distinct from Japan's NHI pricing, China's NRDL listing, or Australia's PBS/PBAC system. Korea's Big 5 hospital concentration of KOL influence and the role of KSMO/KSH/KCS specialist societies create a unique research environment. All HCP research benefits from Korean-language execution for clinical accuracy and engagement.

BioNixus covers oncology (KSMO specialist networks, SNUH/Samsung/Asan cancer centres), immunology and biologics (HIRA biosimilar switching policies), cardiovascular (KCS specialist networks), haematology (KSH specialist networks), rheumatology (KRA networks), rare disease (NHIS Named Patient Programme research), respiratory, metabolic/diabetes (including GLP-1), medical devices, and consumer health across the South Korean market.

Yes. BioNixus maintains physician and specialist networks across Korea's Big 5 hospitals: Seoul National University Hospital (SNUH), Samsung Medical Center (SMC), Asan Medical Center, Severance Hospital (Yonsei University), and Seoul St. Mary Hospital (Catholic University of Korea). For scarce specialties such as oncology or rare disease, BioNixus recruits through Korean cancer centre networks, KSMO/KSH/KCS specialist society directories, and regional tertiary hospital networks.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including HIRA/NHIS payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, IRB requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-hospital recruitment across Korea's Big 5 may require extended planning timelines.

Yes. South Korean modules can run with comparable cells in Japan, China, Australia, Singapore, the USA, UK, EU5, and Canada — using consistent instruments for Asia-Pacific and global portfolio committees managing multi-market access strategy from one research partner.

Yes. BioNixus designs and executes South Korean patient and HCP research in compliance with Korea's Personal Information Protection Act (PIPA / 개인정보 보호법) and relevant IRB data privacy standards. All research involves documented informed consent, de-identified reporting, and secure data handling.